Fisetin

Acute or intermittent treatment of aged mice with fisetin reduced senescence markers in multiple tissues, improved tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan with no adverse side effects.

Intermittent fisetin treatment in aged mice reduced frailty, increased grip strength, and reduced expression of genes associated with cellular senescence in skeletal muscle, with improvements comparable to genetic clearance and pharmaceutical interventions.

In animal models of Alzheimer's disease and cognitive impairment, fisetin treatment improved cognition, reduced amyloid-beta and tau phosphorylation, decreased inflammatory markers, and increased synaptic markers and long-term potentiation through neuroprotective mechanisms.

In animal models of Alzheimer's disease and cognitive impairment, fisetin treatment improved cognition, reduced amyloid-beta and tau phosphorylation, decreased inflammatory markers, and increased synaptic markers and long-term potentiation through neuroprotective mechanisms.

Intermittent fisetin treatment in aged mice reduced frailty, increased grip strength, and reduced expression of genes associated with cellular senescence in skeletal muscle, with improvements comparable to genetic clearance and pharmaceutical interventions.

Acute or intermittent treatment of aged mice with fisetin reduced senescence markers in multiple tissues, improved tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan with no adverse side effects.

Acute or intermittent treatment of aged mice with fisetin reduced senescence markers in multiple tissues, improved tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan with no adverse side effects.

Intermittent fisetin treatment in aged mice reduced frailty, increased grip strength, and reduced expression of genes associated with cellular senescence in skeletal muscle, with improvements comparable to genetic clearance and pharmaceutical interventions.

Acute or intermittent treatment of aged mice with fisetin reduced senescence markers in multiple tissues, improved tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan with no adverse side effects.

Intermittent fisetin treatment in aged mice reduced frailty, increased grip strength, and reduced expression of genes associated with cellular senescence in skeletal muscle, with improvements comparable to genetic clearance and pharmaceutical interventions.

In animal models of Alzheimer's disease and cognitive impairment, fisetin treatment improved cognition, reduced amyloid-beta and tau phosphorylation, decreased inflammatory markers, and increased synaptic markers and long-term potentiation through neuroprotective mechanisms.

In animal models of Alzheimer's disease and cognitive impairment, fisetin treatment improved cognition, reduced amyloid-beta and tau phosphorylation, decreased inflammatory markers, and increased synaptic markers and long-term potentiation through neuroprotective mechanisms.

Intermittent fisetin treatment in aged mice reduced frailty, increased grip strength, and reduced expression of genes associated with cellular senescence in skeletal muscle, with improvements comparable to genetic clearance and pharmaceutical interventions.